Cargando…

Effect of Sofosbuvir plus Ribavirin therapy on hepatitis C patients in Pakistan: a retrospective study

BACKGROUND: The annual global deaths from viral hepatitis is 1.4 million. Pakistan has the second highest burden of hepatitis C in the world. There is dire need to evaluate the response of new direct acting antivirals for the treatment of hepatitis C patients in Pakistan. World Health Organization h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jamil, Zubia, Waheed, Yasir, Malik, Maryam, Durrani, Asghar A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PeerJ Inc. 2018
Materias:	Virology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971832/ https://www.ncbi.nlm.nih.gov/pubmed/29844992 http://dx.doi.org/10.7717/peerj.4853

Ejemplares similares

Effectiveness, tolerability and safety of Direct Acting Antivirals in Mexican individuals with Hepatitis C virus genotype-1 and previous pegylated interferon and ribavirin therapy
por: Melendez-Mena, Daniel, et al.
Publicado: (2021)

Miliary tuberculosis infection during hepatitis C treatment with sofosbuvir and ledipasvir plus ribavirin
por: Ballester-Ferré, Maria Pilar, et al.
Publicado: (2017)

Determining the Actual Prevalence of Hepatitis B in Khyber Pakhtunkhwa-Pakistan: A Meta-Analysis
por: Khan, Najeeb Ullah, et al.
Publicado: (2018)

The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
por: Walker, David R, et al.
Publicado: (2015)

Effectiveness of sofosbuvir/pegylated-interferon plus ribavirin in treatment of hepatitis C virus genotype 4 patients
por: Abdel-Moneim, Adel, et al.
Publicado: (2018)

Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis
por: Flamm, Steven, et al.
Publicado: (2023)

Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C
por: Tang, L., et al.
Publicado: (2018)

Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis
por: He, Qiu-Feng, et al.
Publicado: (2016)

Sofosbuvir and ribavirin in acute hepatitis C–infected patient with decompensated cirrhosis
por: Liu, Hui, et al.
Publicado: (2016)

Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
por: Liu, Chen-Hua, et al.
Publicado: (2021)

A retrospective study of prevalence and pattern of international consensus on ANA patterns among patients with hepatitis C virus infection
por: Hsiao, Shun-Wen, et al.
Publicado: (2022)

Successful Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin Retreatment for a Chronic Hepatitis C Genotype 2a Patient Who Relapsed after Sofosbuvir Plus Ribavirin Treatment
por: Ishikawa, Toru, et al.
Publicado: (2018)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
por: McEwan, Phil, et al.
Publicado: (2017)

Characterization of Samples Identified as Hepatitis C Virus Genotype 1 without Subtype by Abbott RealTime HCV Genotype II Assay Using the New Abbott HCV Genotype Plus RUO Test
por: Mokhtari, Camelia, et al.
Publicado: (2016)

Ledipasvir/sofosbuvir and ribavirin for the treatment of ribavirin-refractory persistent hepatitis E virus infection
por: Gallacher, Jennifer, et al.
Publicado: (2023)

Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme
por: Hézode, Christophe, et al.
Publicado: (2017)

Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis
por: Seo, Hee Yeon, et al.
Publicado: (2020)

Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study
por: Kim, Young Min, et al.
Publicado: (2018)

Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma
por: Petruzziello, Arnolfo
Publicado: (2018)

Direct-acting antiviral treatment for Hepatitis C Virus in geriatric patients: a real-world retrospective comparison between early and late elderly patients
por: Yen, Hsu-Heng, et al.
Publicado: (2021)

Significant Improvement in Diagnosis of Hepatitis C Virus Infection by a One-Step Strategy in a Central Laboratory: an Optimal Tool for Hepatitis C Elimination?
por: López-Martínez, Rosa, et al.
Publicado: (2019)

Efficacy and Safety of Sofosbuvir and Ribavirin for Treating Chronic Hepatitis C, Genotype 3: Experience of a Tertiary Care Hospital at Karachi, Pakistan
por: Butt, Nazish, et al.
Publicado: (2019)

Sofosbuvir–velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals
por: Izumi, Namiki, et al.
Publicado: (2018)

Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
por: Yeon, Jong Eun
Publicado: (2018)

Serological evidence of hepatitis A, B, and C virus infection in older adults in Khon Kaen, Thailand and the estimated rates of chronic hepatitis B and C virus infection in Thais, 2017
por: Posuwan, Nawarat, et al.
Publicado: (2019)

Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C
por: de Medeiros, Lucas Pereira Jorge, et al.
Publicado: (2018)

Characterization of Hepatitis C Virus Recombination in Cameroon by Use of Nonspecific Next-Generation Sequencing
por: Iles, James C., et al.
Publicado: (2015)

Hepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals
por: Schietroma, Ivan, et al.
Publicado: (2018)

The Changing Epidemiology of Hepatitis C Virus Acquisition Among HIV-Infected Individuals in Brazil
por: Ferrufino, Rosario Quiroga, et al.
Publicado: (2023)

Blood markers of endothelial dysfunction and their correlation to cerebrovascular reactivity in patients with chronic hepatitis C infection
por: Pavicic Ivelja, Mirela, et al.
Publicado: (2021)

A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection
por: Kao, Jia‐Horng, et al.
Publicado: (2016)

Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection
por: Ahmed, Ossama A, et al.
Publicado: (2018)

Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis
por: Wei, Bin, et al.
Publicado: (2018)

Comparison of Next-Generation Sequencing Technologies for Comprehensive Assessment of Full-Length Hepatitis C Viral Genomes
por: Thomson, Emma, et al.
Publicado: (2016)

Effect of Silymarin as an Adjunct Therapy in Combination with Sofosbuvir and Ribavirin in Hepatitis C Patients: A Miniature Clinical Trial
por: Ahmed, Sarfraz, et al.
Publicado: (2022)

Safety of Sofosbuvir and Ribavirin Combination Therapy in a Patient Who Developed Anemia due to Ribavirin
por: Suii, Hirokazu, et al.
Publicado: (2017)

Patterns of hepatitis B virus S gene escape mutants and reverse transcriptase mutations among genotype D isolates in Jordan
por: Ababneh, Nidaa A., et al.
Publicado: (2019)

Hepatitis C Virus Core Mutations Associated with False-Negative Serological Results for Genotype 3a Core Antigen
por: Nguyen, Linh Thuy, et al.
Publicado: (2015)

Sofosbuvir in combination with ribavirin or simeprevir: real-life study of patients with hepatitis C genotype 4
por: Abdel-Moneim, Adel, et al.
Publicado: (2019)

The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2
por: Han, Sung Yong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kvuu8gagic5037lt6f5qoo1t6p